SOURCE: Transparency Market Research, PVT LTD.

Transparency Market Research

June 11, 2015 07:20 ET

Transparency Market Research, PVT LTD.: North America Dominated the Global Glioblastoma Treatment Market

The Global Glioblastoma Treatment Market Expected to Reach USD 0.91 Billion in 2022: Transparency Market Research

ALBANY, NY--(Marketwired - June 11, 2015) - According to a new market report published by Transparency Market Research “Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022” the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022.

Browse to see full Research Report of Glioblastoma Treatment Market with Figures and Segmentation: http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

The global glioblastoma multiforme (GBM) treatment market is largely concentrated in the western countries of North America and Europe. These regions account for more than 60% of the market share. Majority of the GBM treatment drugs are initially approved in these regions, as the U .S. and Europe are most lucrative pharmaceutical markets. Early market entry, and high drug prices are the main factors driving growth of the GBM treatment market in the U.S. Rising diagnosis and treatment rates, and affordability of expensive medical treatments are other forces supporting the market in the U.S. and Europe. U.K. is the largest market for GBM treatment in Europe, followed by Germany, and France; while Spain accounts for the smallest share in the GBM treatment market. Although North America and Europe are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. Various non-profit organizations such as American Brain Tumor Association, National Brain Tumor Society, Brain Tumor Foundation of Canada and others in the U.S. are involved in creating awareness regarding GBM diagnosis and treatment options to boost the market growth. Furthermore, approval of generic alternatives would impede the market growth and approval of new drugs would lead to substantial market growth.

Browse the full Press Release of Global Glioblastoma Treatment Market: http://www.transparencymarketresearch.com/pressrelease/glioblastoma-treatment-industry.htm

India, China and Japan are major countries driving the GBM market in Asia Pacific. Japan is the second-largest individual pharmaceutical market, while India and China are the most populated countries resulting into large patient pool. These countries are also the two fastest growing economies globally. As these countries have a large low- and middle-income population, demand for low cost treatments is high. However, this trend is not likely in case of severe diseases such as GBM as the available treatments are limited and require higher cost.

Get More Information about the Glioblastoma Treatment Market or Request for Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4807

The Rest of the World market comprises Latin America, Africa and the Middle East. Lack of awareness related to GBM, availability of advanced medical treatments and financial affordability are the major restraining forces in Latin American and African market. Overall it is expected that North America would lead the market throughout the forecast period, while Asia Pacific would be the fastest growing regional market in the GBM treatment market.

Other Market Research Press Releases by Transparency Market Research:

The pipeline review of glioblastoma treatment market has been segmented as below:

Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs

  • Bevacizumab (Avastin)
  • Temozolomide (Temodar and Temodal and Temcad)
  • Carmustine (BiCNU)

Global Glioblastoma Treatment Market Revenue and Forecast, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Global Pipeline Review of Glioblastoma Treatment

Overview

Late Stage (Phase III)

  • DCVax
  • Rindopepimut (CDX-110)
  • Others

Early Stage (Phase I, II and Pre clinical)

  • ABT-414
  • MM-398
  • ARC-100
  • AV0113
  • Cotara
  • Crenolanib
  • SGT-53
  • Endostatin
  • ANG1005
  • Others

Browse All Pharmaceutical Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us:

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Web: http://www.transparencymarketresearch.com/

Image Available: http://www.marketwire.com/library/MwGo/2015/6/11/11G044533/Images/Pharmaceuticals-856344830037.jpg

Contact Information

  • Contact:

    Mr. Nachiket Ghumare
    State Tower, 90 State Street,
    Suite 700, Albany NY - 12207
    USA/Canada Toll Free: 866-552-3453
    Tel: +1-518-618-1030
    Email: sales@transparencymarketresearch.com